UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 15, 2006
AFFYMETRIX, INC.
(Exact name of registrant as specified in its charter)
DELAWARE |
| 0-28218 |
| 77-0319159 |
(State of incorporation) |
| (Commission File Number) |
| (IRS Employer Identification No.) |
3420 Central Expressway
Santa Clara, California 95051
(Address of principal executive offices) (Zip Code)
(408) 731-5000
Registrant’s telephone number, including area code
N/A
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.
The Board of Directors of Affymetrix, Inc. (“Affymetrix” or the “Company”) elected Robert H. Trice, Ph.D. to serve as a member of the Company’s Board of Directors effective as of February 15, 2006. Dr. Trice is currently Senior Vice President of Business Development at Lockheed Martin Corporation and Chairman and CEO of Lockheed Martin Global Inc. The Board has not yet determined what committees Dr. Trice may serve on. There are no arrangements between Dr. Trice and any other persons pursuant to which Dr. Trice was selected as a director. There are no transactions, or proposed transactions, to which the Company is or was to be a party and in which Dr. Trice had a direct or indirect material interest that are required to be disclosed under Item 404(a) of Regulation S-K. A copy of the press release announcing Dr. Trice’s election is filed herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
Exhibit No. |
| Description |
|
|
|
99.1 |
| Press Release dated February 15, 2006 |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| AFFYMETRIX, INC. | ||
|
| ||
|
| ||
| By: | /s/ Barbara A. Caulfield |
|
|
| Name: Barbara A. Caulfield | |
|
| Title: Executive Vice President and General Counsel | |
|
| ||
Dated: February 16, 2006 |
|
3
EXHIBIT INDEX
Exhibit No. |
| Description |
|
|
|
99.1 |
| Press Release dated February 15, 2006 |
4